ArticleFrontiers in nephrology2023

A randomized controlled trial of preemptive rituximab to prevent recurrent focal segmental glomerulosclerosis post-kidney transplant (PRI-VENT FSGS): protocol and study design.

Michelle N Rheault et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.